GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tibet Weixinkang Pharmaceutical Co 603676.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.24

0.00%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.14bn

FY2016FY2025

Net income

CN¥232.9m

FY2016FY2025

Free cash flow

CN¥101.6m

FY2016FY2025

Shareholders' equity

CN¥1.48bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.14bnCN¥1.30bnCN¥1.32bnCN¥1.40bnCN¥1.03bnCN¥715.7mCN¥741.0mCN¥746.3mCN¥420.4mCN¥426.4m
Gross profitCN¥697.9mCN¥696.0mCN¥671.4mCN¥726.5mCN¥530.9mCN¥330.6mCN¥347.0mCN¥341.5mCN¥242.4mCN¥264.7m
Research and developmentCN¥110.6mCN¥116.0mCN¥112.8mCN¥72.5mCN¥38.0mCN¥23.2mCN¥29.1mCN¥24.4mCN¥25.0mCN¥33.8m
Operating incomeCN¥259.3mCN¥280.9mCN¥175.0mCN¥162.6mCN¥102.4mCN¥59.5mCN¥55.9mCN¥76.9mCN¥88.7mCN¥113.3m
Net incomeCN¥232.9mCN¥246.2mCN¥214.0mCN¥177.0mCN¥95.9mCN¥58.4mCN¥55.7mCN¥73.4mCN¥101.6mCN¥114.9m
Diluted earnings per share0.560.580.500.410.260.130.080.170.220.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.87bnCN¥1.85bnCN¥1.78bnCN¥1.66bnCN¥1.50bnCN¥1.36bnCN¥1.30bnCN¥1.23bnCN¥1.02bnCN¥552.4m
Cash and short-term investments—CN¥1.02bnCN¥894.7mCN¥806.3mCN¥711.5mCN¥575.5mCN¥529.6mCN¥154.3mCN¥75.4mCN¥89.3m
Total liabilitiesCN¥390.5mCN¥468.2mCN¥436.5mCN¥444.1mCN¥428.3mCN¥376.9mCN¥374.6mCN¥337.3mCN¥158.6mCN¥92.9m
Debt—CN¥5.3mCN¥3.8mCN¥5.8mCN¥4.8mCN¥6.4m—CN¥26.6m——
Shareholders' equityCN¥1.48bnCN¥1.39bnCN¥1.34bnCN¥1.22bnCN¥1.07bnCN¥983.2mCN¥930.1mCN¥897.6mCN¥858.0mCN¥459.4m
Shares outstanding419m424m425m432m368m437m685m440m461m351m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥185.5mCN¥372.8mCN¥256.7mCN¥246.2mCN¥170.7mCN¥133.7mCN¥106.3mCN¥83.2mCN¥63.3mCN¥103.8m
Capital spending−CN¥83.9m−CN¥58.2m−CN¥70.8m−CN¥77.7m−CN¥55.6m−CN¥54.3m−CN¥43.7m−CN¥94.5m−CN¥77.8m−CN¥26.4m
Free cash flowCN¥101.6mCN¥314.6mCN¥185.9mCN¥168.5mCN¥115.1mCN¥79.3mCN¥62.7m−CN¥11.3m−CN¥14.5mCN¥77.4m
Dividends paid−CN¥163.4m−CN¥177.8m−CN¥97.8m−CN¥69.6m−CN¥40.2m−CN¥19.0m−CN¥23.3m−CN¥34.4m−CN¥3.5m−CN¥56.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥262.1mCN¥322.1mCN¥273.3mCN¥276.2mCN¥290.4mCN¥295.8mCN¥305.9mCN¥361.1m
Gross profitCN¥151.6mCN¥193.9mCN¥164.5mCN¥172.9mCN¥183.5mCN¥177.0mCN¥152.0mCN¥201.3m
Operating incomeCN¥77.8mCN¥78.3mCN¥19.1mCN¥67.4mCN¥112.6mCN¥94.9mCN¥47.3mCN¥89.5m
Net incomeCN¥74.6mCN¥68.3mCN¥13.7mCN¥36.4mCN¥98.2mCN¥84.5mCN¥2.9mCN¥79.8m
Diluted earnings per share0.180.160.030.090.230.200.010.19
Cash from operations———CN¥13.0mCN¥54.0mCN¥49.0m—CN¥106.0m
Capital spending−CN¥15.0m−CN¥15.0m−CN¥36.0m−CN¥18.0m−CN¥14.0m−CN¥13.0m−CN¥24.0m−CN¥16.0m
Free cash flow———−CN¥5.0mCN¥40.0mCN¥36.0m—CN¥90.0m
Total assetsCN¥1.96bnCN¥1.95bnCN¥1.87bnCN¥1.91bnCN¥1.88bnCN¥1.90bnCN¥1.85bnCN¥1.93bn
Cash and short-term investments———CN¥1.02bnCN¥1.03bnCN¥1.05bnCN¥1.02bnCN¥1.06bn
Debt———CN¥2.4mCN¥2.4mCN¥1.8m——
Shareholders' equityCN¥1.54bnCN¥1.54bnCN¥1.48bnCN¥1.53bnCN¥1.49bnCN¥1.47bnCN¥1.39bnCN¥1.48bn

Financial ratios

Data as of 17 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Gross margin61.5%53.5%50.8%51.9%51.4%46.2%—
Operating margin25.0%21.3%16.3%13.1%11.1%9.9%—
Net margin20.5%18.9%16.2%12.7%9.3%8.2%—
Return on equity15.8%17.8%16.0%14.5%9.0%5.9%—
Return on assets12.5%13.3%12.0%10.6%6.4%4.3%—
Free cash flow yield7.3%11.6%8.8%8.5%7.0%4.9%—
Revenue growth-12.7%-1.7%-5.4%35.3%44.4%-3.4%—
Earnings growth-5.4%15.0%20.9%84.5%64.2%4.9%—
Current ratio3.70x3.08x3.04x2.77x2.41x2.43x—
Debt to equity—0.00x————0.03x
Equity ratio79.1%74.7%75.4%73.3%71.4%72.3%—
Interest coverage1263.69x1231.97x502.22x662.54x55.30x54.83x—
R&D as a share of sales9.7%8.9%8.5%5.2%3.7%3.2%—
Buybacks as a share of market value1.3%0.2%1.7%-17.6%15.8%36.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-6.7%9.7%9.9%
Operating income16.8%34.2%7.9%
Net income9.6%31.9%7.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin57.2%54.1%52.9%53.0%
Operating margin22.2%17.0%15.1%15.4%
Net margin19.7%16.9%14.8%15.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings18.917.120.738.935.667.2130.567.572.7
Price to sales3.93.33.44.93.35.59.86.617.6

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 29 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.180.3270.4470.2350.160.0950.0450.055

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.